Dato Dr. Kim Tan is the founder Chairman of SpringHill Management Ltd (UK), a fund management company in biotech and social venture capital investments. Dato Kim is the Chairman of the NCI Cancer Hospital (Malaysia) and a board director of a number of companies in Malaysia, India, the UK, South Africa and the USA. He is an advisor to a number of government agencies in Asia on biotechnology and is a board member of the Asia Pacific Economic Cooperation (APEC) Life Science Forum. He is the Chairman of the West Surrey & North Hants Innovation and Growth Team (UK). Kim Tan has a PhD in biochemistry and was the recipient of a PhD scholarship and four post-doctoral fellowships from the Medical Research Council (UK). He is the inventor of sheep monoclonal antibodies and a Fellow of the Royal Society of Medicine.
Kim Tan is the co-founder of Transformational Business Network, the UK charity with social transformational businesses in developing countries, including the Kuzuko Game Reserve (South Africa) and the Hagar Social Enterprise Group (Cambodia). He was a former director of Saracens Rugby Ltd (UK) and the former Chairman of Jubilee Action, the UK-based human rights organization working with street children in India, Africa, Philippines and Brazil.
Mr Cameron Denny MBA, FCCA, FCMA, MCT, MCIPS
He is a qualified Accountant with additional qualifications in Corporate Treasury and Procurement, as well as an MBA. He has worked in such blue chip companies as Nabisco, Nynex and Cable and Wireless, as well as being trained in KPMG. He spent 15 years in the Telecommunications industry, which included a period with one of the largest telecommunications companies in France, Intercomm, subsequently part of UPC, Europe’s largest cable communications company. Prior to joining SpringHill he worked in the Public Sector. He has worked in the Middle East, the Caribbean, the USA, France and the UK. He has a degree in Biology specialising in Microbiology.